Abstract
Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer's disease (AD). Methods: A total of 225 drug-naive AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the delayed verbal recall task of the Wechsler Memory Scale-revised, and the 13-item modified Alzheimer's Disease Assessment Scale-cognitive subscale at week 12. Results: At 12 weeks, significant improvement in the delayed verbal recall task was noted in the active group compared with control (P=.021). Modified Alzheimer's Disease Assessment Scale-cognitive subscale and other outcome scores (e.g., Clinician Interview Based Impression of Change plus Caregiver Input, 12-item Neuropsychiatric Inventory, Alzheimer's disease Co-operative Study-Activities of Daily Living, Quality of Life in Alzheimer's Disease) were unchanged. The control group neither deteriorated nor improved. Compliance was excellent (95%) and the product was well tolerated. Conclusions: Supplementation with a medical food including phosphatide precursors and cofactors for 12 weeks improved memory (delayed verbal recall) in mild AD patients. This proof-of-concept study justifies further clinical trials.
Original language | English |
---|---|
Pages (from-to) | 1-10 |
Journal | Alzheimer's & Dementia |
Volume | 6 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2010 |
Keywords
- Alzheimer's disease
- Nutritional intervention
- Synapse formation
- Membrane phosphatide synthesis
- B vitamins
- Omega-3 fatty acids
- Nucleotides
- Uridine
- Phospholipids
- Choline
- Antioxidants
- ADAS-cog, delayed verbal recall
- Medical food
- Dietary management
- Randomized clinical trial
- Dementia